Sunshine Biopharma (NASDAQ:SBFM) Releases Earnings Results

Sunshine Biopharma (NASDAQ:SBFM) announced its quarterly earnings data on Wednesday. The company reported ($0.25) EPS for the quarter, Zacks reports. Sunshine Biopharma had a negative net margin of 17.86% and a negative return on equity of 27.14%.

Sunshine Biopharma Price Performance

Shares of Sunshine Biopharma stock traded down $0.39 during trading hours on Wednesday, hitting $0.66. The company had a trading volume of 479,239 shares, compared to its average volume of 55,397. The company’s 50-day moving average is $1.04 and its two-hundred day moving average is $1.26. Sunshine Biopharma has a twelve month low of $0.66 and a twelve month high of $2.43. The company has a market cap of $3.24 million, a P/E ratio of -0.45 and a beta of 1.37.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in shares of Sunshine Biopharma in the 4th quarter valued at $29,000. Two Sigma Investments LP acquired a new position in shares of Sunshine Biopharma in the 3rd quarter valued at $32,000. Finally, Citadel Advisors LLC boosted its holdings in shares of Sunshine Biopharma by 23.1% in the 3rd quarter. Citadel Advisors LLC now owns 78,087 shares of the company’s stock valued at $116,000 after buying an additional 14,656 shares in the last quarter. Institutional investors and hedge funds own 41.98% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Sunshine Biopharma in a report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $7.00.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.